{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:03:46Z","timestamp":1783487026983,"version":"3.55.0"},"reference-count":17,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Most thyroglobulin (Tg) assays have a sensitivity of 0.5\u20131 ng\/ml. A minority of patients with undetectable T4-suppressed Tg levels have a recombinant human TSH (rhTSH)-stimulated Tg above 2 ng\/ml and identifiable residual disease.<\/jats:p>\n               <jats:p>Objective: The objective was to determine whether a Tg assay with improved sensitivity could eliminate the need for rhTSH stimulation when baseline Tg is below 0.1 ng\/ml.<\/jats:p>\n               <jats:p>Design: A retrospective study of two academic endocrine practices was conducted.<\/jats:p>\n               <jats:p>Population: A total of 194 patients undergoing rhTSH stimulation participated in the study.<\/jats:p>\n               <jats:p>Results: Of the 80 patients with Tg below 0.1 ng\/ml, two (2.5%) had rhTSH-stimulated Tg above 2 ng\/ml. One other patient with stimulation to 0.3 ng\/ml and negative 123I scan had an ultrasound-detected malignant lymph node resected. None had 131I\/123I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. If T4-suppressed Tg was 0.1\u20130.5 or 0.6\u20132.0 ng\/ml, rhTSH Tg was above 2 ng\/ml in 24.2 and 82.4%, respectively.<\/jats:p>\n               <jats:p>Conclusions: Patients with differentiated thyroid carcinoma and a T4-suppressed serum Tg below 0.1 ng\/ml rarely have a rhTSH-stimulated Tg above 2 ng\/ml, and none of these patients had 131I or 123I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. We recommend monitoring such patients with a T4-suppressed Tg level and periodic neck ultrasonography. An increase in T4-suppressed serum Tg to a detectable level or the appearance of abnormal lymph nodes by physical or ultrasound exam should prompt further investigation.<\/jats:p>","DOI":"10.1210\/jc.2006-0993","type":"journal-article","created":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T04:23:42Z","timestamp":1162355022000},"page":"82-87","source":"Crossref","is-referenced-by-count":120,"title":["Monitoring Thyroglobulin in a Sensitive Immunoassay Has Comparable Sensitivity to Recombinant Human TSH-Stimulated Thyroglobulin in Follow-Up of Thyroid Cancer Patients"],"prefix":"10.1210","volume":"92","author":[{"given":"Robert C.","family":"Smallridge","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism (R.C.S., S.E.M., M.A.M., G.S.G., T.P.F.), Mayo Clinic College of Medicine, Jacksonville, Florida 32224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shon E.","family":"Meek","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (R.C.S., S.E.M., M.A.M., G.S.G., T.P.F.), Mayo Clinic College of Medicine, Jacksonville, Florida 32224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (R.C.S., S.E.M., M.A.M., G.S.G., T.P.F.), Mayo Clinic College of Medicine, Jacksonville, Florida 32224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey S.","family":"Gates","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (R.C.S., S.E.M., M.A.M., G.S.G., T.P.F.), Mayo Clinic College of Medicine, Jacksonville, Florida 32224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Fox","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (R.C.S., S.E.M., M.A.M., G.S.G., T.P.F.), Mayo Clinic College of Medicine, Jacksonville, Florida 32224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Grebe","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology (S.G.), Mayo Clinic College of Medicine, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahab","family":"Fatourechi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology (V.F.), Mayo Clinic College of Medicine, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613385813000_R1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006.","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"2020071613385813000_R2","first-page":"1139","article-title":"Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period.","volume":"112","author":"Hay","year":"1992","journal-title":"Surgery"},{"key":"2020071613385813000_R3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJM199709253371304","article-title":"Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.","volume":"337","author":"Ladenson","year":"1997","journal-title":"N Engl J Med"},{"key":"2020071613385813000_R4","first-page":"3877","article-title":"A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.","volume":"84","author":"Haugen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613385813000_R5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1210\/jcem.86.2.7189","article-title":"Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.","volume":"86","author":"Robbins","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613385813000_R6","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1210\/jcem.86.12.8065","article-title":"Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.","volume":"86","author":"Pacini","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613385813000_R7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/105072502753451959","article-title":"Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin.","volume":"12","author":"Haugen","year":"2002","journal-title":"Thyroid"},{"key":"2020071613385813000_R8","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1210\/jcem.87.4.8274","article-title":"Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.","volume":"87","author":"Pacini","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613385813000_R9","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1210\/jcem.87.7.8702","article-title":"Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?","volume":"87","author":"Robbins","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613385813000_R10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/105072502320288438","article-title":"Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin.","volume":"12","author":"Wartofsky","year":"2002","journal-title":"Thyroid"},{"key":"2020071613385813000_R11","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1210\/jc.2002-021702","article-title":"A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.","volume":"88","author":"Mazzaferri","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613385813000_R12","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1210\/jc.2002-021925","article-title":"Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.","volume":"88","author":"Pacini","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613385813000_R13","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1210\/jc.2005-0492","article-title":"A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.","volume":"90","author":"Kloos","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613385813000_R14","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1210\/jc.2003-031041","article-title":"Author\u2019s response: a consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.","volume":"88","author":"Mazzaferri","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613385813000_R15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1148\/radiol.2263020036","article-title":"Lung cancer screening with CT: Mayo Clinic experience.","volume":"226","author":"Swensen","year":"2003","journal-title":"Radiology"},{"key":"2020071613385813000_R16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1515\/CCLM.2006.107","article-title":"Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.","volume":"44","author":"Giovanella","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"2020071613385813000_R17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/thy.2006.16.109","article-title":"Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.","volume":"16","author":"Cooper","year":"2006","journal-title":"Thyroid"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/1\/82\/11059139\/jcem0082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/1\/82\/11059139\/jcem0082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:18:45Z","timestamp":1594945125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/1\/82\/2598072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2006-0993","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}